CARSTEN BOESS
CIK 1277495 · SVP, Chief Financial Officer · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.74M
Companies
8
Total Filings
54
Lifetime Open-Market Net
-$16.98M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RCKT | Director | 52,862 | $3.14 | $166.0K | $0 | 6 | 2026-07-06 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Director | 0 | — | — | $0 | 1 | 2026-02-27 |
| RCKTW | Director | 30,000 | $0.00 | $99 | $0 | 3 | 2025-07-18 |
| RNA | Director | 6,692 | $11.49 | $76.9K | $0 | 5 | 2025-06-12 |
| KNSA | 10%+ Owner | 79,589 | $79.44 | $6.32M | $0 | 1 | 2018-05-29 |
| ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Director | — | — | — | $0 | 3 | 2017-06-21 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | SVP, Chief Financial Officer | 0 | — | — | -$12.17M | 17 | 2015-06-23 |
| PODD | Vice President, International | 18,941 | $167.47 | $3.17M | -$4.81M | 16 | 2011-04-27 |
Recent Filings · Page 2 of 6
54 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-17 | RNA | Grant (A) | — | $0 | EDGAR |
| 2022-06-15 | RCKT | Grant (A) | — | $0 | EDGAR |
| 2021-06-16 | RNA | Grant (A) | — | $0 | EDGAR |
| 2021-06-16 | RCKT | Grant (A) | — | $0 | EDGAR |
| 2020-06-18 | RCKT | Grant (A) | — | $0 | EDGAR |
| 2019-01-30 | RCKT | Grant (A) | — | $0 | EDGAR |
| 2018-05-29 | KNSA | Mixed | +6,392 | $0 | EDGAR |
| 2018-04-02 | RCKT | Grant (A) | — | $0 | EDGAR |
| 2017-06-21 | ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-27 | ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.